Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas

Trial Profile

A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CPI 613 (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AVENGER 500
  • Sponsors Rafael Pharmaceuticals
  • Most Recent Events

    • 24 Oct 2019 According to a Rafael Pharmaceuticals media release, the trial is now active in four sites in South Korea: Kyungpook National University Chilgok Hospital, Seoul National University Hospital, Seoul St. Mary's Hospital (SSMH) of The Catholic University of Korea, and National Cancer Center Korea (NCCK). The study has reached overall enrollment of 100 patients.
    • 08 Oct 2019 According to a Rafael Pharmaceuticals media release, study is still open for patient enrollment in sites across the United States, France, Israel and South Korea.
    • 08 Oct 2019 According to a Rafael Pharmaceuticals media release, 100 patients has been enrolled.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top